Clinical Progress And Depressed Prices Make This Biotech Theme Worth A Look

Clinical Progress And Depressed Prices Make This Biotech Theme Worth A Look

Our theme on Gene Editing stocks remains down by 30% year-to-date, as rising interest rates have made investors prioritize value stocks and companies with strong cash flows over loss-making futuristic themes.